You are here

  • Home
  • Archive
  • Volume 81, Issue 12
  • Response to: ‘Correspondence on ‘Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial’’ by Bredemeier

Article metrics

Article menu

Download PDFPDF

Correspondence response
Response to: ‘Correspondence on ‘Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial’’ by Bredemeier
Free

 

Online download statistics by month:

Online download statistics by month: October 2020 to March 2024

AbstractFullPdf
Oct 202036035591
Nov 202018818826
Dec 2020343425
Jan 2021424117
Feb 2021464617
Mar 2021424214
Apr 2021313113
May 202166689
Jun 202126266
Jul 2021404013
Aug 202133337
Sep 2021282811
Oct 2021403925
Nov 2021454418
Dec 202180804
Jan 202237378
Feb 2022363711
Mar 202242424
Apr 202226264
May 2022363611
Jun 202231326
Jul 202234341
Aug 202237376
Sep 2022313112
Oct 2022373810
Nov 202230730731
Dec 202230330318
Jan 2023757315
Feb 202347468
Mar 202330304
Apr 202325256
May 2023353514
Jun 202325254
Jul 202316168
Aug 202311112
Sep 202327275
Oct 202329297
Nov 202331318
Dec 2023212211
Jan 2024171511
Feb 202410109
Mar 20248956
Total24652459586